A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool

Trial Profile

A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Chondrosarcoma; Endometrial cancer; Ewing's sarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 Planned initiation date changed from 1 Jan 2017 to 1 Dec 2017.
    • 08 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top